NPTX2 and myeloid sarcoma: Lower dose requirements may also open up the possibility of utilising AAV-ophNdi1 to treat other mitochondrial/OXPHOS disorders where systemic delivery will be a necessity due to multiple organ involvement, including MELAS, MERF, NARP [84] and MS [85], among others.